Investor Presentation Full Year 2017

B-cell function Investor Presentation Full year 2017 Slide 41 Insulin is the ultimate care for people with diabetes Progression of type 2 diabetes and treatment intensification Distribution of patients and value across treatment classes Diet and exercise OAD: Oral anti-diabetic changing diabetes Time OAD GLP-1 100% Insulin GLP-1 80% 37% 68% 60% 12% 40% Insulin 4% 51% 20% 28% 0% Patients Value Note: Patient distribution across treatment classes is indicative and based on data for US, UK, Germany and France. Value figures based on IQVIA (formerly IMS) MAT Nov, 2017 Source: IQVIA (formerly IMS) PharMetrix claims data, IQVIA (formerly IMS) disease analyser, IQVIA (formerly IMS) MIDAS OAD novo nordisk

View entire presentation